Stronger together: Analytical techniques for recombinant adeno associated virus

With recent FDA approval of two recombinant adeno‐associated virus (rAAV)‐based gene therapies, these vectors have proven that they are suitable to address monogenic diseases. However, rAAVs are relatively new modalities, and their production and therapy costs significantly exceed those of conventio...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutanu, Andrei, Boelsterli, David, Schmidli, Claudio, Montealegre, Cristina, Dang Thai, Mike H. N., Bobaly, Balazs, Koch, Marius, Schwarz, Maria A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Vaccines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300034/
https://www.ncbi.nlm.nih.gov/pubmed/34821392
http://dx.doi.org/10.1002/elps.202100302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300034/
https://www.ncbi.nlm.nih.gov/pubmed/34821392
http://dx.doi.org/10.1002/elps.202100302

Ejemplares similares